Your browser doesn't support javascript.
loading
Prospective and Mendelian randomization analyses on the association of circulating fatty acid binding protein 4 (FABP-4) and risk of colorectal cancer.
Nimptsch, Katharina; Aleksandrova, Krasimira; Pham, Thu Thi; Papadimitriou, Nikos; Janke, Jürgen; Christakoudi, Sofia; Heath, Alicia; Olsen, Anja; Tjønneland, Anne; Schulze, Matthias B; Katzke, Verena; Kaaks, Rudolf; van Guelpen, Bethany; Harbs, Justin; Palli, Domenico; Macciotta, Alessandra; Pasanisi, Fabrizio; Yohar, Sandra Milena Colorado; Guevara, Marcela; Amiano, Pilar; Grioni, Sara; Jakszyn, Paula Gabriela; Figueiredo, Jane C; Samadder, N Jewel; Li, Christopher I; Moreno, Victor; Potter, John D; Schoen, Robert E; Um, Caroline Y; Weiderpass, Elisabete; Jenab, Mazda; Gunter, Marc J; Pischon, Tobias.
Afiliação
  • Nimptsch K; Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany. katharina.nimptsch@mdc-berlin.de.
  • Aleksandrova K; Department Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology, Bremen, Germany.
  • Pham TT; Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany.
  • Papadimitriou N; Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany.
  • Janke J; Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, Berlin, Germany.
  • Christakoudi S; Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Heath A; Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany.
  • Olsen A; Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Biobank Technology Platform, Berlin, Germany.
  • Tjønneland A; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Schulze MB; Department of Inflammation Biology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Katzke V; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Kaaks R; Danish Cancer Society Research Center, Copenhagen, Denmark.
  • van Guelpen B; Department of Public Health, University of Århus, Århus, Denmark.
  • Harbs J; Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Palli D; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Macciotta A; Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nutehtal, Germany.
  • Pasanisi F; Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.
  • Yohar SMC; Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Guevara M; Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Amiano P; Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
  • Grioni S; Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.
  • Jakszyn PG; Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
  • Figueiredo JC; Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
  • Samadder NJ; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  • Li CI; Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
  • Moreno V; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
  • Potter JD; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Schoen RE; Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.
  • Um CY; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Weiderpass E; Instituto de Salud Pública de Navarra, Pamplona, 31003, Spain.
  • Jenab M; Navarra Institute for Health Research (IdiSNA), Pamplona, 31008, Spain.
  • Gunter MJ; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Pischon T; Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain.
BMC Med ; 21(1): 391, 2023 10 13.
Article em En | MEDLINE | ID: mdl-37833736
ABSTRACT

BACKGROUND:

Fatty acid binding protein 4 (FABP-4) is a lipid-binding adipokine upregulated in obesity, which may facilitate fatty acid supply for tumor growth and promote insulin resistance and inflammation and may thus play a role in colorectal cancer (CRC) development. We aimed to investigate the association between circulating FABP-4 and CRC and to assess potential causality using a Mendelian randomization (MR) approach.

METHODS:

The association between pre-diagnostic plasma measurements of FABP-4 and CRC risk was investigated in a nested case-control study in 1324 CRC cases and the same number of matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A two-sample Mendelian randomization study was conducted based on three genetic variants (1 cis, 2 trans) associated with circulating FABP-4 identified in a published genome-wide association study (discovery n = 20,436) and data from 58,131 CRC cases and 67,347 controls in the Genetics and Epidemiology of Colorectal Cancer Consortium, Colorectal Cancer Transdisciplinary Study, and Colon Cancer Family Registry.

RESULTS:

In conditional logistic regression models adjusted for potential confounders including body size, the estimated relative risk, RR (95% confidence interval, CI) per one standard deviation, SD (8.9 ng/mL) higher FABP-4 concentration was 1.01 (0.92, 1.12) overall, 0.95 (0.80, 1.13) in men and 1.09 (0.95, 1.25) in women. Genetically determined higher FABP-4 was not associated with colorectal cancer risk (RR per FABP-4 SD was 1.10 (0.95, 1.27) overall, 1.03 (0.84, 1.26) in men and 1.21 (0.98, 1.48) in women). However, in a cis-MR approach, a statistically significant association was observed in women (RR 1.56, 1.09, 2.23) but not overall (RR 1.23, 0.97, 1.57) or in men (0.99, 0.71, 1.37).

CONCLUSIONS:

Taken together, these analyses provide no support for a causal role of circulating FABP-4 in the development of CRC, although the cis-MR provides some evidence for a positive association in women, which may deserve to be investigated further.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Limite: Female / Humans / Male Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Limite: Female / Humans / Male Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha